These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 16899405)
41. The emergence of mupirocin resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Trinidad: a first report. Orrett FA Jpn J Infect Dis; 2008 Mar; 61(2):107-10. PubMed ID: 18362397 [TBL] [Abstract][Full Text] [Related]
42. Sesquiterpene farnesol inhibits recycling of the C55 lipid carrier of the murein monomer precursor contributing to increased susceptibility to beta-lactams in methicillin-resistant Staphylococcus aureus. Kuroda M; Nagasaki S; Ohta T J Antimicrob Chemother; 2007 Mar; 59(3):425-32. PubMed ID: 17242033 [TBL] [Abstract][Full Text] [Related]
43. Polyamine effects on antibiotic susceptibility in bacteria. Kwon DH; Lu CD Antimicrob Agents Chemother; 2007 Jun; 51(6):2070-7. PubMed ID: 17438056 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H; J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703 [TBL] [Abstract][Full Text] [Related]
45. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin. Fujimura S; Watanabe A; Fuse K; Kikuchi T; Gomi K; Tokue Y Int J Antimicrob Agents; 2008 Apr; 31(4):391-2. PubMed ID: 18308516 [No Abstract] [Full Text] [Related]
46. Beta-lactam antibiotic susceptibility testing of MRSA? Agrawal G; Jalgaonkar SV Indian J Med Microbiol; 2006 Oct; 24(4):304. PubMed ID: 17185859 [No Abstract] [Full Text] [Related]
47. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Cornaglia G; Rossolini GM Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369 [TBL] [Abstract][Full Text] [Related]
48. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Vaudaux P; Gjinovci A; Bento M; Li D; Schrenzel J; Lew DP Antimicrob Agents Chemother; 2005 Sep; 49(9):3789-93. PubMed ID: 16127054 [TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus. Park YS; Shin WS; Kim SK J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852 [TBL] [Abstract][Full Text] [Related]
50. In vitro activities of 28 antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) from a clinical setting in Malaysia. Neela V; Sasikumar M; Ghaznavi GR; Zamberi S; Mariana S Southeast Asian J Trop Med Public Health; 2008 Sep; 39(5):885-92. PubMed ID: 19058585 [TBL] [Abstract][Full Text] [Related]
51. Adult methicillin-resistant Staphylococcus aureus bacteremia in Taiwan: clinical significance of non-multi-resistant antibiogram and Panton-Valentine leukocidin gene. Wang JL; Wang JT; Chen SY; Hsueh PR; Kung HC; Chen YC; Chang SC Diagn Microbiol Infect Dis; 2007 Dec; 59(4):365-71. PubMed ID: 17878063 [TBL] [Abstract][Full Text] [Related]
52. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Appelbaum PC Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634 [TBL] [Abstract][Full Text] [Related]
53. Antagonism of chemical genetic interaction networks resensitize MRSA to β-lactam antibiotics. Lee SH; Jarantow LW; Wang H; Sillaots S; Cheng H; Meredith TC; Thompson J; Roemer T Chem Biol; 2011 Nov; 18(11):1379-89. PubMed ID: 22118672 [TBL] [Abstract][Full Text] [Related]
54. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456 [TBL] [Abstract][Full Text] [Related]
55. New agents for Staphylococcus aureus endocarditis. Drees M; Boucher H Curr Opin Infect Dis; 2006 Dec; 19(6):544-50. PubMed ID: 17075329 [TBL] [Abstract][Full Text] [Related]
56. Natural lipopeptide antibiotic tripropeptin C revitalizes and synergistically potentiates the activity of beta-lactams against methicillin-resistant Staphylococcus aureus. Hashizume H; Takahashi Y; Harada S; Nomoto A J Antibiot (Tokyo); 2015 Jun; 68(6):373-8. PubMed ID: 25586024 [TBL] [Abstract][Full Text] [Related]
57. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Tverdek FP; Crank CW; Segreti J Crit Care Clin; 2008 Apr; 24(2):249-60, vii-viii. PubMed ID: 18361944 [TBL] [Abstract][Full Text] [Related]